Pilot Trial Opens: Can Retinal Imaging Detect Transthyretin Amyloid Cardiomyopathy Non-Invasively? AstraZeneca Study Targets 500 Patients Across Four Countries

References

1. 1.AstraZeneca. (2025). A multicenter pilot study to investigate ocular involvement and the potential of ocular imaging for non-invasive screening for transthyretin amyloid cardiomyopathy (ATTR-CM) (NCT07690436). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07690436
2. 2.Patel, P., Bhatt, N., Bhatt, A., et al. (2021). Ocular manifestations of systemic amyloidosis: A review. Survey of Ophthalmology, 66(5), 777–785. https://doi.org/10.1016/j.survophthal.2021.01.004
3. 3.Gertz, M. A. (2020). Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. American Journal of Hematology, 95(7), 848–860. https://doi.org/10.1002/ajh.25680
4. 4.Damy, T., Costes, B., Hagège, A. A., et al. (2016). Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. European Heart Journal, 37(23), 1826–1834. https://doi.org/10.1093/eurheartj/ehv583
5. 5.Maurer, M. S., Schwartz, J. H., Gundapaneni, B., et al. (2018). Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. New England Journal of Medicine, 379(11), 1007–1016. https://doi.org/10.1056/NEJMoa1805689
6. 6.Gillmore, J. D., Maurer, M. S., Falk, R. H., et al. (2016). Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation, 133(24), 2404–2412. https://doi.org/10.1161/CIRCULATIONAHA.116.021612